Department of Dermatology and Venereology, Nantong University , Nantong, Jiangsu , China .
Biomarkers. 2014 Feb;19(1):70-6. doi: 10.3109/1354750X.2013.871752. Epub 2013 Dec 27.
We investigated the expression and clinical significance of Cancerous inhibitor of protein phosphatase 2A (CIP2A) in Cutaneous malignant melanoma (CMM).
CIP2A expression was analyzed by immunohistochemistry and western blot. We tested the invasion and migration capability of A375 cells with Matrigel invasion assay, Scratch migration assay and Matrigel migration assay after down-regulating CIP2A expression using siRNA.
CIP2A immunostaining level was correlated with Breslow thickness, Clark's Level and lymphovascular invasion. High-CIP2A expression implied poor survival for patients. Downregulation of CIP2A attenuated metastasis of CMM cells.
CIP2A may serve as a novel marker to predict the prognosis for CMM patients.
研究癌性蛋白磷酸酶 2A 抑制剂（CIP2A）在皮肤恶性黑色素瘤（CMM）中的表达及其临床意义。
采用免疫组织化学和 Western blot 法分析 CIP2A 的表达。用 siRNA 下调 CIP2A 表达后，通过 Matrigel 侵袭实验、划痕迁移实验和 Matrigel 迁移实验检测 A375 细胞的侵袭和迁移能力。
CIP2A 免疫染色水平与 Breslow 厚度、Clark 分级和血管淋巴管浸润相关。高 CIP2A 表达提示患者预后不良。下调 CIP2A 可减弱 CMM 细胞的转移。
CIP2A 可作为预测 CMM 患者预后的新标志物。
